Lacosamide vs Phenytoin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channels · full Epilepsy pipeline
Lacosamide · Vimpat
Marketed by UCB
NCT00136019 · Phase 3 · completed
Multicentre, double-blind, placebo-controlled trial (SP754): 405 patients randomised 1:2:1 to placebo, lacosamide 400 mg or 600 mg/day; the prespecified primary outcome was met. The registry record omits the arms; the design is from the publication.
The old registry record lists only the lacosamide intervention; the design and arms are from the publication.
Reported efficacy
Efficacy is evaluated based on reduction in seizure frequency, 50 percent reduction in seizures, number and percentage of seizure-free days, and achievement of seizure-free status.: Median % reduction in seizure frequency/28 days: lacosamide 400mg/day -37.3% (p=0.008), 600mg/day -37.8% (p=0.006), vs placebo -20.8%; >=50% responder rates 38.3% (400mg) and 41.2% (600mg) vs 18.3% placebo (p<0.001). (met)
Result source: NCT00136019
Phenytoin
Marketed by Viatris and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Epilepsy
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Lacosamide | Phenytoin |
|---|---|---|
| Seizure frequency, % change | —Not posted · NCT00136019 | —Not posted · NCT00210782 |
| 50% responder rate | —Not posted · NCT00136019 | —Not posted · NCT00210782 |
| Seizure freedom | —Not posted · NCT00136019 | —Not posted · NCT00210782 |
Seizure frequency, % change
- Lacosamide
- —Not posted · NCT00136019
- Phenytoin
- —Not posted · NCT00210782
50% responder rate
- Lacosamide
- —Not posted · NCT00136019
- Phenytoin
- —Not posted · NCT00210782
Seizure freedom
- Lacosamide
- —Not posted · NCT00136019
- Phenytoin
- —Not posted · NCT00210782
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Lacosamide: 4 of 4 rows · Phenytoin: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Lacosamide | Phenytoin |
|---|---|---|
| Dropout rate | 34.3%a NCT02408549 · Phase 3 · combination show 45 more results—Lacosamide (SS) Safety Follow-up P NCT02408523 · Phase 3 —Lacosamide (SS) Taper Period NCT02408523 · Phase 3 —Lacosamide (SS) Transition Period NCT02408523 · Phase 3 —Lacosamide (SS) Treatment Period NCT02408523 · Phase 3 7.1% NCT01190098 · Phase 4 · registry result, not featured evidence 16.7%First Add-on NCT00955357 · Phase 4 · registry result, not featured evidence · add on 18.3%Later Add-on NCT00955357 · Phase 4 · registry result, not featured evidence · add on 36.8%Lacosamide: >=2 to <4 Years NCT04627285 · Phase 3 · registry result, not featured evidence 13.8%Lacosamide: >=4 to <6 Years NCT04627285 · Phase 3 · registry result, not featured evidence 26.9% NCT01964560 · Phase 3 · registry result, not featured evidence — NCT02477839 · Phase 3 · registry result, not featured evidence — NCT02582866 · Phase 3 · registry result, not featured evidence — NCT01832038 · Phase 3 · registry result, not featured evidence 36.8% NCT02124564 · Phase 3 · registry result, not featured evidence 11.7% NCT01921205 · Phase 3 · registry result, not featured evidence 24.4%Lacosamide NCT01465997 · Phase 3 · registry result, not featured evidence —Lacosamide (SS) NCT01465997 · Phase 3 · registry result, not featured evidence 40.1% NCT01243177 · Phase 3 · registry result, not featured evidence 34.8% NCT00530855 · Phase 3 · registry result, not featured evidence 0% NCT02192814 · Phase 3 · registry result, not featured evidence 25% NCT01345058 · Phase 3 · registry result, not featured evidence · combination 17.8%400 mg/day NCT01710657 · Phase 3 · registry result, not featured evidence 6.6%200 mg/day NCT01710657 · Phase 3 · registry result, not featured evidence 22.5% NCT01484977 · Phase 3 · registry result, not featured evidence 39.2%400 mg/day NCT00520741 · Phase 3 · registry result, not featured evidence 34.9%300 mg/day NCT00520741 · Phase 3 · registry result, not featured evidence 57.4% NCT00515619 · Phase 3 · registry result, not featured evidence 28.9% NCT00655486 · Phase 3 · registry result, not featured evidence 55.2% NCT00522275 · Phase 3 · registry result, not featured evidence 16%400 mg NCT00655551 · Phase 3 · registry result, not featured evidence 6%300 mg NCT00655551 · Phase 3 · registry result, not featured evidence 0%200 mg NCT00655551 · Phase 3 · registry result, not featured evidence —Lacosamide Age Cohort ≥ 1 Month - NCT02710890 · Phase 2/3 · registry result, not featured evidence —Lacosamide Age Cohort ≥ 8 - < 17 Y NCT02710890 · Phase 2/3 · registry result, not featured evidence — NCT00938912 · Phase 2 · registry result, not featured evidence 10%Lacosamide 1 Month - <4 Years NCT01969851 · Phase 2 · registry result, not featured evidence 33.3%Lacosamide 12 Years - <18 Years NCT01969851 · Phase 2 · registry result, not featured evidence 12.5%Lacosamide 4 Years - <12 Years NCT01969851 · Phase 2 · registry result, not featured evidence —400mg NCT01458522 · Phase 2 · registry result, not featured evidence 40%>=1 Month to <4 Years (Safety Set) NCT00938431 · Phase 2 · registry result, not featured evidence 88.9%>=12 Years to <=17 Years (Safety S NCT00938431 · Phase 2 · registry result, not featured evidence 39.1%>=4 Years to <12 Years (Safety Set NCT00938431 · Phase 2 · registry result, not featured evidence 25.6% NCT01118962 · Phase 2 · registry result, not featured evidence 18.4% NCT01118949 · Phase 2 · registry result, not featured evidence 67.6% NCT00552305 · Phase 2 · registry result, not featured evidence | 38.2%a NCT00510783 · Phase 4 · registry result, not featured evidence |
| Discontinued due to AEs | 6.3%a NCT02408549 · Phase 3 · combination show 45 more results—Lacosamide (SS) Safety Follow-up P NCT02408523 · Phase 3 —Lacosamide (SS) Taper Period NCT02408523 · Phase 3 —Lacosamide (SS) Transition Period NCT02408523 · Phase 3 —Lacosamide (SS) Treatment Period NCT02408523 · Phase 3 4.8% NCT01190098 · Phase 4 · registry result, not featured evidence 9.4%First Add-on NCT00955357 · Phase 4 · registry result, not featured evidence · add on 12.8%Later Add-on NCT00955357 · Phase 4 · registry result, not featured evidence · add on 0%Lacosamide: >=2 to <4 Years NCT04627285 · Phase 3 · registry result, not featured evidence 6.9%Lacosamide: >=4 to <6 Years NCT04627285 · Phase 3 · registry result, not featured evidence 4.3% NCT01964560 · Phase 3 · registry result, not featured evidence — NCT02477839 · Phase 3 · registry result, not featured evidence — NCT02582866 · Phase 3 · registry result, not featured evidence — NCT01832038 · Phase 3 · registry result, not featured evidence 10.5% NCT02124564 · Phase 3 · registry result, not featured evidence 4.1% NCT01921205 · Phase 3 · registry result, not featured evidence 4.3%Lacosamide NCT01465997 · Phase 3 · registry result, not featured evidence —Lacosamide (SS) NCT01465997 · Phase 3 · registry result, not featured evidence — NCT01243177 · Phase 3 · registry result, not featured evidence — NCT00530855 · Phase 3 · registry result, not featured evidence — NCT02192814 · Phase 3 · registry result, not featured evidence — NCT01345058 · Phase 3 · registry result, not featured evidence · combination 15.6%400 mg/day NCT01710657 · Phase 3 · registry result, not featured evidence 4.4%200 mg/day NCT01710657 · Phase 3 · registry result, not featured evidence 6.7% NCT01484977 · Phase 3 · registry result, not featured evidence 17.6%400 mg/day NCT00520741 · Phase 3 · registry result, not featured evidence 15.1%300 mg/day NCT00520741 · Phase 3 · registry result, not featured evidence 9% NCT00515619 · Phase 3 · registry result, not featured evidence 10.3% NCT00655486 · Phase 3 · registry result, not featured evidence 11.4% NCT00522275 · Phase 3 · registry result, not featured evidence 16%400 mg NCT00655551 · Phase 3 · registry result, not featured evidence 6%300 mg NCT00655551 · Phase 3 · registry result, not featured evidence 0%200 mg NCT00655551 · Phase 3 · registry result, not featured evidence —Lacosamide Age Cohort ≥ 1 Month - NCT02710890 · Phase 2/3 · registry result, not featured evidence —Lacosamide Age Cohort ≥ 8 - < 17 Y NCT02710890 · Phase 2/3 · registry result, not featured evidence — NCT00938912 · Phase 2 · registry result, not featured evidence 0%Lacosamide 1 Month - <4 Years NCT01969851 · Phase 2 · registry result, not featured evidence 14.3%Lacosamide 12 Years - <18 Years NCT01969851 · Phase 2 · registry result, not featured evidence 0%Lacosamide 4 Years - <12 Years NCT01969851 · Phase 2 · registry result, not featured evidence —400mg NCT01458522 · Phase 2 · registry result, not featured evidence 33.3%>=1 Month to <4 Years (Safety Set) NCT00938431 · Phase 2 · registry result, not featured evidence 66.7%>=12 Years to <=17 Years (Safety S NCT00938431 · Phase 2 · registry result, not featured evidence 34.8%>=4 Years to <12 Years (Safety Set NCT00938431 · Phase 2 · registry result, not featured evidence 5.1% NCT01118962 · Phase 2 · registry result, not featured evidence 10.2% NCT01118949 · Phase 2 · registry result, not featured evidence 13% NCT00552305 · Phase 2 · registry result, not featured evidence | —a NCT00510783 · Phase 4 · registry result, not featured evidence |
| Serious AEs | 22.6%a NCT02408549 · Phase 3 · combination show 45 more results9.1%Lacosamide (SS) Safety Follow-up P NCT02408523 · Phase 3 0%Lacosamide (SS) Taper Period NCT02408523 · Phase 3 3%Lacosamide (SS) Transition Period NCT02408523 · Phase 3 6.6%Lacosamide (SS) Treatment Period NCT02408523 · Phase 3 7.1% NCT01190098 · Phase 4 · registry result, not featured evidence 8.3%First Add-on NCT00955357 · Phase 4 · registry result, not featured evidence · add on 5.3%Later Add-on NCT00955357 · Phase 4 · registry result, not featured evidence · add on 10.5%Lacosamide: >=2 to <4 Years NCT04627285 · Phase 3 · registry result, not featured evidence 17.2%Lacosamide: >=4 to <6 Years NCT04627285 · Phase 3 · registry result, not featured evidence 20.6% NCT01964560 · Phase 3 · registry result, not featured evidence 4.7% NCT02477839 · Phase 3 · registry result, not featured evidence 14.2% NCT02582866 · Phase 3 · registry result, not featured evidence 17.5% NCT01832038 · Phase 3 · registry result, not featured evidence 10.5% NCT02124564 · Phase 3 · registry result, not featured evidence 6.4% NCT01921205 · Phase 3 · registry result, not featured evidence —Lacosamide NCT01465997 · Phase 3 · registry result, not featured evidence 11.5%Lacosamide (SS) NCT01465997 · Phase 3 · registry result, not featured evidence 8.1% NCT01243177 · Phase 3 · registry result, not featured evidence 17.4% NCT00530855 · Phase 3 · registry result, not featured evidence 0% NCT02192814 · Phase 3 · registry result, not featured evidence 0% NCT01345058 · Phase 3 · registry result, not featured evidence · combination 5%400 mg/day NCT01710657 · Phase 3 · registry result, not featured evidence 1.1%200 mg/day NCT01710657 · Phase 3 · registry result, not featured evidence 6.7% NCT01484977 · Phase 3 · registry result, not featured evidence 6.6%400 mg/day NCT00520741 · Phase 3 · registry result, not featured evidence 3.8%300 mg/day NCT00520741 · Phase 3 · registry result, not featured evidence 23.1% NCT00515619 · Phase 3 · registry result, not featured evidence 10.3% NCT00655486 · Phase 3 · registry result, not featured evidence 23.1% NCT00522275 · Phase 3 · registry result, not featured evidence 4%400 mg NCT00655551 · Phase 3 · registry result, not featured evidence 0%300 mg NCT00655551 · Phase 3 · registry result, not featured evidence 0%200 mg NCT00655551 · Phase 3 · registry result, not featured evidence 0%Lacosamide Age Cohort ≥ 1 Month - NCT02710890 · Phase 2/3 · registry result, not featured evidence 0%Lacosamide Age Cohort ≥ 8 - < 17 Y NCT02710890 · Phase 2/3 · registry result, not featured evidence 22.5% NCT00938912 · Phase 2 · registry result, not featured evidence 0%Lacosamide 1 Month - <4 Years NCT01969851 · Phase 2 · registry result, not featured evidence 4.8%Lacosamide 12 Years - <18 Years NCT01969851 · Phase 2 · registry result, not featured evidence 0%Lacosamide 4 Years - <12 Years NCT01969851 · Phase 2 · registry result, not featured evidence 22.2%400mg NCT01458522 · Phase 2 · registry result, not featured evidence 20%>=1 Month to <4 Years (Safety Set) NCT00938431 · Phase 2 · registry result, not featured evidence 0%>=12 Years to <=17 Years (Safety S NCT00938431 · Phase 2 · registry result, not featured evidence 13%>=4 Years to <12 Years (Safety Set NCT00938431 · Phase 2 · registry result, not featured evidence 7.7% NCT01118962 · Phase 2 · registry result, not featured evidence 2% NCT01118949 · Phase 2 · registry result, not featured evidence 33.8% NCT00552305 · Phase 2 · registry result, not featured evidence | 0%a NCT00510783 · Phase 4 · registry result, not featured evidence |
| Most frequent reported AEs | show 44 more resultsdrooling 11.1% (placebo 0%) grand mal convulsion 11.1% (placebo 0%) laceration 11.1% (placebo 0%) NCT02408523 · Phase 3 dizziness 3% (placebo 0%) nasopharyngitis 1% (placebo 0%) vertigo 1% (placebo 0%) NCT02408523 · Phase 3 dizziness 21.5% (placebo 0%) somnolence 14.9% (placebo 0%) headache 13.2% (placebo 0%) NCT02408523 · Phase 3 dizziness 42.9% (placebo 30%) headache 40.5% (placebo 40%) common cold/flu 21.4% (placebo 10%) NCT01190098 · Phase 4 · registry result, not featured evidence dizziness 31.3% headache 13.5% vertigo 9.4% NCT00955357 · Phase 4 · registry result, not featured evidence · add on dizziness 33.1% somnolence 15% headache 11.4% NCT00955357 · Phase 4 · registry result, not featured evidence · add on upper respiratory tract infection 26.3% NCT04627285 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 13.8% NCT04627285 · Phase 3 · registry result, not featured evidence pyrexia 15.9% upper respiratory tract infection 15.4% nasopharyngitis 10.6% NCT01964560 · Phase 3 · registry result, not featured evidence somnolence 14.1% (placebo 3.9%) irritability 5.5% (placebo 4.7%) pyrexia 5.5% (placebo 11.8%) NCT02477839 · Phase 3 · registry result, not featured evidence nasopharyngitis 33% dizziness 26.4% upper respiratory tract infection 20.9% NCT01832038 · Phase 3 · registry result, not featured evidence dizziness 52.6% somnolence 42.1% nasopharyngitis 36.8% NCT02124564 · Phase 3 · registry result, not featured evidence somnolence 16.4% (placebo 6.4%) nasopharyngitis 11.7% (placebo 5.8%) dizziness 10.5% (placebo 7.6%) NCT01921205 · Phase 3 · registry result, not featured evidence nasopharyngitis 7.2% headache 6.1% dizziness 4.3% NCT01465997 · Phase 3 · registry result, not featured evidence headache 13.5% dizziness 11.9% fatigue 7.7% NCT01243177 · Phase 3 · registry result, not featured evidence dizziness 27.6% headache 17.1% nausea 14.3% NCT00530855 · Phase 3 · registry result, not featured evidence abdominal pain upper 11.1% injection site erythema 11.1% injection site pain 11.1% NCT02192814 · Phase 3 · registry result, not featured evidence erectile dysfunction 11.1% fatigue 11.1% memory/cognitive difficulties/confusion 11.1% NCT01345058 · Phase 3 · registry result, not featured evidence · combination 400 mg/day dizziness 35% (placebo 13%) nasopharyngitis 16.1% (placebo 13%) headache 10.6% (placebo 6%) NCT01710657 · Phase 3 · registry result, not featured evidence 200 mg/day dizziness 18% (placebo 13%) nasopharyngitis 15.3% (placebo 13%) somnolence 9.8% (placebo 4.9%) NCT01710657 · Phase 3 · registry result, not featured evidence dizziness 23.3% headache 15% fatigue 8.3% NCT01484977 · Phase 3 · registry result, not featured evidence 400 mg/day dizziness 27% nausea 14.4% headache 14.1% NCT00520741 · Phase 3 · registry result, not featured evidence 300 mg/day headache 19.8% dizziness 17.9% convulsion 16% NCT00520741 · Phase 3 · registry result, not featured evidence dizziness 24.2% headache 14.4% nasopharyngitis 13.8% NCT00515619 · Phase 3 · registry result, not featured evidence dizziness 44.3% diplopia 17.5% vomiting 16.5% NCT00655486 · Phase 3 · registry result, not featured evidence dizziness 50% headache 21.8% contusion 18.5% NCT00522275 · Phase 3 · registry result, not featured evidence 400 mg dizziness 60% somnolence 36% nausea 24% NCT00655551 · Phase 3 · registry result, not featured evidence 300 mg dizziness 46% somnolence 34% fatigue 18% NCT00655551 · Phase 3 · registry result, not featured evidence 200 mg dizziness 20% gait disturbance 8% headache 8% NCT00655551 · Phase 3 · registry result, not featured evidence functional gastrointestinal disorder 2.1% pyrexia 2.1% respiratory tract infection 2.1% NCT02710890 · Phase 2/3 · registry result, not featured evidence blood triglycerides increased 3.6% blood cholesterol increased 1.8% functional gastrointestinal disorder 0% NCT02710890 · Phase 2/3 · registry result, not featured evidence nasopharyngitis 24.9% upper respiratory tract infection 23.6% pyrexia 21.9% NCT00938912 · Phase 2 · registry result, not featured evidence nasopharyngitis 50% pyrexia 40% somnolence 40% NCT01969851 · Phase 2 · registry result, not featured evidence headache 19% nasopharyngitis 14.3% pharyngotonsillitis 14.3% NCT01969851 · Phase 2 · registry result, not featured evidence pyrexia 25% cough 16.7% upper respiratory tract infection 16.7% NCT01969851 · Phase 2 · registry result, not featured evidence 400mg respiratory failure 6.7% acute respiratory failure 4.4% bradycardia 4.4% NCT01458522 · Phase 2 · registry result, not featured evidence irritability 20% pharyngotonsillitis 20% diarrhoea 13.3% NCT00938431 · Phase 2 · registry result, not featured evidence balance disorder 22.2% dizziness 22.2% rash 22.2% NCT00938431 · Phase 2 · registry result, not featured evidence vomiting 30.4% diarrhoea 17.4% dizziness 13% NCT00938431 · Phase 2 · registry result, not featured evidence dizziness 25.6% upper respiratory tract infection 25.6% headache 17.9% NCT01118962 · Phase 2 · registry result, not featured evidence dizziness 38.8% nausea 26.5% headache 16.3% NCT01118949 · Phase 2 · registry result, not featured evidence dizziness 39.7% headache 20.8% nausea 17.3% NCT00552305 · Phase 2 · registry result, not featured evidence | a dizziness 9.2% fatigue 9.2% burning at the iv site 6.6% NCT00510783 · Phase 4 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Lacosamide
show 1 more result
show 3 more results
+ 25 further endpoints in the CSV export.
Phenytoin
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lacosamide's landscape · Phenytoin's landscape